Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation

    Journal Title:  Blood Cancer J Primary Author:  Sugimori C Author(s):  Sugimo...

    Research Article last updated 07/31/2012 - 12:36pm.

  2. Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

    ... worse outcome if their cancer cells carried a mutation to the CDKN2A gene. The results may help doctors tailor treatment ... This is the first time that mutations in the CDKN2A gene mutation have been linked to poorer survival in people with AML treated with ...

    Research Article last updated 09/29/2017 - 10:32am.

  3. FDA approves new drug for relapsed or refractory AML

    ... leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. This is the first FDA ... for relapsed or refractory AML specifically with an IDH2 mutation. The FDA concurrently approved a companion diagnostic, the RealTime ...

    Article last updated 08/30/2017 - 8:30am.

  4. Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications

    ... HLA-B *40:02 alleles. Three patients had more than 1 mutation targeting the same HLA allele. Interestingly, HLA-B *14:02 and ... who inherited the targeted HLA alleles, regardless of HLA mutation status, had a more severe disease course with more frequent clonal ...

    Research Article last updated 10/23/2017 - 10:56am.

  5. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

    ... 17% intermediate, 38% low and 16% very low. At least one mutation /variant was detected in 147 (82%) patients; 23% harbored three or ... 41% and 20% of patients harbored at least one adverse mutation/variant for overall and leukemia-free survival, respectively. Number ...

    Research Article last updated 09/18/2017 - 11:05am.

  6. Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype

    ... binding domains and the majority of cases had only one mutation , irrespective of their karyotype and MDS subtype. The variant ...

    Research Article last updated 10/02/2017 - 10:56am.

  7. A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination with Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms

    ... (WHO) criteria. Documentation of a TP53 gene mutation by NGS based on central or local evaluation. For TP53 mutant ...

    Clinical Trial last updated 04/21/2018 - 6:04pm.

  8. T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways

    ... thrombosis . The etiology of PNH is a somatic mutation in the phosphatidylinositol glycan class A gene ( PIG-A ) on the ...

    Research Article last updated 07/27/2017 - 2:06pm.

  9. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

    ... advanced hematologic malignancies that harbor an IDH2 mutation . The study includes a dose escalation phase to determine the ...

    Clinical Trial last updated 05/03/2016 - 11:40am.

  10. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

    ... in advanced hematologic malignancies that harbor an IDH1 mutation . The first portion of the study is a dose escalation phase where ...

    Clinical Trial last updated 05/03/2016 - 11:37am.